Originally published as JHC exPRESS on November 12, 2007. doi:10.1369/jhc.7A7290.2007
Volume 56 (3): 223-231, 2008 Copyright ©The Histochemical Society, Inc. Aberrant Expression of Histo-blood Group A Type 3 Antigens in Vascular Endothelial Cells in Inflammatory Sites
Department of Forensic Medicine (MN,YI,TH,TM,AK) and Department of Dermatology (AT,CK,FF), Wakayama Medical University, Wakayama, Japan, and Institute of Legal Medicine, University of Munich, Munich, Germany (WE) Correspondence to: Akihiko Kimura, PhD, Department of Forensic Medicine, Wakayama Medical University, Kimiidera 811-1, 641-8509 Wakayama, Japan. E-mail: legkim{at}wakayama-med.ac.jp
Histo-blood group ABH antigens are widely distributed in human tissues. The epitopes of ABH antigens are carried by at least four different peripheral core isotypes of internal carbohydrate backbones (type 1–4). Each type of ABH antigen is expressed tissue specifically, and aberrant expression of ABH antigens is often observed during oncogenesis. We immunohistochemically examined the expression of A type 3 antigens in wounded and diseased skin tissues (A and AB blood groups). In uninjured skin, the expression of A type 3 antigens was restricted to the eccrine sweat gland. In addition to the sweat glands, A type 3 antigens were found in vascular endothelial cells of the wound sites. The extent of A type 3 antigens expression related to postinfliction intervals. A significantly higher expression rate of A type 3 antigens in endothelial cells was also observed in diseased skin, suggesting that inflammation might induce A type 3 antigen expression in endothelial cells. Double-color immunofluorescence staining of the specimens showed that von Willebrand factor (vWF) was a core-protein of A type 3 determinants aberrantly expressed in endothelial cells in inflamed tissues, suggesting that aberrant expression of A type 3 antigens is involved in stabilization of vWF in inflammation. (J Histochem Cytochem 56:223–231, 2008)
Key Words: histo-blood group A type 3 antigen vascular endothelial cell wound healing inflammation von Willebrand factor
HISTO-BLOOD GROUP ABH determinants are well characterized as oligo-saccharides and carried on various glycopeptides and glycolipids, which are widely distributed in human tissues (Oriol 1995 1-3Galβ1-R; type 4, Galβ1-3GalNAcβ1-3Gal 1-R) (Clausen and Hakomori 1989
Aberrant expression of ABH antigens is often observed in the oncogenesis of various organs (Cooper et al. 1991 In this study, we immunohistochemically examined A type 3 antigen expression in vascular endothelial cells in wounded and diseased skin tissues and showed the inflammation-specific expression of A type 3 antigens on von Willebrand factor (vWF) in vascular endothelial cells.
Antibodies Histo-blood group A type 3–specific monoclonal antibody (AR-1, IgM) was produced by immunizing mice with blood group A erythrocyte membranes. The specificity of AR-1 was determined by TLC immunostaining of glycosphingolipids extracted from blood group A erythrocyte membranes, which was confirmed by comparing with authentic anti-A type 3 monoclonal antibody TH-1 (Clausen et al. 1985
Human Skin Wound Specimens
Human Diseased Skin Tissues
Immunohistochemistry Immunostaining for vWF was performed with rabbit anti-human vWF (1:500) and anti-rabbit immunoglobulins conjugated to HRP-labeled polymer (Envision+; Dako Cytomation) as described above.
Double-color Immunofluorescence Staining
Morphometrical Analysis
Statistical Analysis
Localization of A Type 3 and H Type 3/4 Antigens in Normal Skin Tissue In normal skin, A type 3 antigens defined by AR-1 were localized in the cytoplasm of dark cells and inner layer cells of ducts in eccrine sweat glands in specimens from secretors, individuals expressing secretor (Se) gene–encoded FUT II, and secreting blood group antigens in saliva (Figures 1A and 1B). On the other hand, only duct cells of eccrine sweat glands expressed A type 3 antigens in specimens from non-secretors, individuals not expressing Se gene–encoded FUT II, and individuals not secreting blood group antigens in saliva (Figures 1C and 1D). In addition to eccrine sweat glands, the cytoplasm of vascular endothelial cells in the dermis near the epidermis was occasionally stained by AR-1 (data not shown). Vascular endothelial cells in the subcutaneous tissue did not express A type 3 antigens. In contrast to A type 3 antigens, H type 3/4 antigens defined by MBr1 were localized in the cytoplasm of dark cells of eccrine sweat glands but not in duct cells (Figures 1E and 1F). The expression of H type 3/4 antigens depended on the secretor status but was irrespective of the ABO blood group. Furthermore, H type 3/4 antigens were not detected in any vascular endothelial cells. Absorption of AR-1 with blood group A red cells completely abolished their reactivity to the sweat glands and vascular endothelial cells (Figure 1G). Moreover, absorption of AR-1 with blood group O red cells had no effect on their reactivity (Figure 1H), indicating that AR-1 reacted specifically to blood group A antigens.
Enhanced Expression of A Type 3 Antigens in Wounded Skin Tissue In Group I (0–12 hr), very few vascular endothelial cells were scattered as positive for AR-1, which was essentially identical to normal skin tissues (data not shown). In contrast to Group I, the ratio of A type 3 antigen–positive vascular endothelial cells was remarkably elevated in Group II (1–4 days) and Group III (7–21 days) (Figures 2B and 2E), which was confirmed by vWF expression in adjacent sections (Figures 2A and 2D). Furthermore, the extent of antigen expression also significantly increased in these specimens. Secretor status did not affect the expression of A type 3 antigen in vascular endothelial cells. A type 3 antigens were detected in the cytoplasm but not on the cell surface of endothelial cells with a granular pattern (Figures 2C and 2F).
The ratio of A type 3 antigen–positive cells in vascular endothelial cells defined by vWF expression was highest in Group II, in which the majority of endothelial cells were positive (Figures 3A –3D). In wound specimens with postinfliction intervals of 7–21 days (Group III), the A type 3 antigen–positive cell ratio decreased gradually, although compared with Group II, it remained high, suggesting that the expression level of A type 3 antigens in vascular endothelial cells is in accordance with the stage of the wound healing process (Figure 3).
Enhanced Expression of A Type 3 Antigens in Diseased Skin Tissues The expression of A type 3 antigens was examined in biopsy specimens of diseased skin such as atopic dermatitis (Figures 4A and 4B), eczema (Figures 4C and 4D), psoriasis vulgaris (Figures 4E and 4F), erythema nodosum (Figures 4G and 4H), drug eruption (data not shown), and leukocyte-elastic vasculitis (data not shown) tissues from blood group A or AB patients. Aberrant expression of A type 3 antigens was observed to various extents in all specimens. In atopic dermatitis (Figures 4A and 4B) and eczema (Figures 4C and 4D), the expression of A type 3 antigens was remarkably enhanced in endothelial cells of dilated capillaries in the papillae. A type 3 antigens were also highly expressed in vascular endothelial cells in the reticular layer of dermis in which inflammatory changes such as perivascular lymphocytic infiltrate, vascular proliferation with thickening of the endothelium, and edema were observed (Figures 4A–4H). These observations suggested that phenotypic alteration of endothelial cells in inflammation induced the expression of A type 3 antigens.
Identification of Core Protein Carrying A Type 3 Antigens Current evidence suggests that ABH determinants are added to N-linked oligosaccharide chains of vWF in the post-Golgi of endothelial cells before secretion and that there may be significant heterogeneity in the amount of ABH antigen expressed on vWF secreted by endothelial cells (Matsui et al. 1992
In normal tissues, A type 3 antigens have been found as glycolipids in erythrocytes (Clausen et al. 1986a
The A type 3 antigen structure on glycolipids is constructed by adding A determinant to the terminal GalNAc of the A type 2 structure; therefore, it is designated repetitive A. The A type 3 antigen structure on mucins is constructed by adding fucose and GalNAc to the terminal galactose of T antigen (Macartney 1986
In wounded and diseased tissues, vascular endothelial cells seem to be affected by various immune modulators, especially cytokines that induce the gene expression of proinflammatory molecules such as adhesion molecules in endothelial cells (Matsunaga et al. 1998
The expression level of A type 3 antigens in wounded skin depended on postinfliction intervals, which is consistent with the fact that various cytokines are generated dependently of postinfliction intervals at wound sites. Immunohistochemical examination of human skin wounds revealed that the expression of interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-
Dabelsteen et al. (1990)
Similar aberrant expression of blood group type 2 antigens, Ley/H, in vascular endothelial cells in inflammatory disease was reported, in which Ley/H antigen expression was rapidly induced by immune modulators, cytokines, lipopolysaccharide, phorbol-12-myristate-13-acetate, calcium ionophore, thrombin, histamine, and growth factors (Koch et al. 1994
It was shown that Ley/H antigens acted as an endothelial-selective, cytokine-inducible, angiogenic mediator, suggesting that Ley/H antigens play roles in the wound healing process. Furthermore, H type 2 antigens mediate leukocyte-endothelial adhesion through intracellular adhesion molecule, suggesting that they are involved in the progression of inflammation (Zhu et al. 2003
The authors thank Dr. Henrik Clausen (Department of Medical Biochemistry and Genetics, the Faculty of Health Sciences, University of Copenhagen, Denmark) for providing monoclonal antibodies, TH-1, and HH14 and invaluable comments on the manuscript and Dr. Toshikazu Kondo for valuable discussion and encouragement.
Received for publication July 9, 2007; accepted October 31, 2007
Adobati E, Panza L, Russo G, Colnaghi MI, Canevari S (1997) In vitro mimicry of CaMBr1 tumor-associated antigen by synthetic oligosaccharides. Glycobiology 7:173–178 Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF (2004) Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 104:100–106 Bonifati C, Carducci M, Mussi A, D'auria L, Ameglio F (1997) IL-1 Bowen DJ (2003) An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 1:33–40[CrossRef][Medline] Bremer EG, Levery SB, Sonnino S, Ghidoni R, Canevari S, Kannagi R, Hakomori S (1984) Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland. J Biol Chem 259:14773–14777 Brown SA, Collins PW, Bowen DJ (2002) Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma. Thromb Haemost 87:990–996[Medline] Bryne M, Lilleholt S, Thrane PS, Koppang HS, Dabelsteen E (1993) Distribution of blood-group-related carbohydrate antigens on oral endothelial cells. Histochem J 25:339–347[CrossRef][Medline] Chang CH, Hang Y, Issekutz AC, Griffith M, Lin KH, Anderson R (2002) Interleukin-1 Clausen H, Hakomori S (1989) ABH and related histo-blood group antigens; immunochemical differences in carrier isotypes and their distribution. Vox Sang 56:1–20[Medline] Clausen H, Holmes E, Hakomori S (1986a) Novel blood group H glycolipid antigens exclusively expressed in blood group A and AB erythrocytes (type 3 chain H). II. Differential conversion of different H substrates by A1 and A2 enzymes, and type 3 chain H expression in relation to secretor status. J Biol Chem 261:1388–1392 Clausen H, Levery SB, Kannagi R, Hakomori S (1986b) Novel blood group H glycolipid antigens exclusively expressed in blood group A and AB erythrocytes (type 3 chain H). I. Isolation and chemical characterization. J Biol Chem 261:1380–1387 Clausen H, Levery SB, Nudelman ED, Stroud M, Salyan ME, Hakomori S (1987) Isolation and characterization of novel glycolipids with blood group A-related structures: galactosyl-A and sialosylgalactosyl-A. J Biol Chem 262:14228–14234 Clausen H, Levery SB, Nudelman E, Tsuchiya S, Hakomori S (1985) Repetitive A epitope (type 3 chain A) defined by blood group A1-specific monoclonal antibody TH-1: chemical basis of qualitative A1 and A2 distinction. Proc Natl Acad Sci USA 82:1199–1203 Conlon PJ, Henney CS, Gillis S (1982) Cytokine-dependent thymocyte responses: characterization of IL 1 and IL 2 target subpopulations and mechanism of action. J Immunol 128:797–801[Abstract] Cooper HS, Malecha MJ, Bass C, Fagel PL, Steplewski Z (1991) Expression of blood group antigens H-2, Le(y), and sialylated-Le(a) in human colorectal carcinoma. An immunohistochemical study using double-labeling techniques. Am J Pathol 138:103–110[Abstract] Cumberbatch M, Dearman RJ, Groves RW, Antonopoulos C, Kimber I (2002) Differential regulation of epidermal langerhans cell migration by interleukins (IL)-1 Dabelsteen E, Broby-Johansen U, Jeppe-Jensen D, Mandel U (1990) Cell surface glycosylation patterns in psoriasis. APMIS 98:221–228[Medline] Dabelsteen E, Gao S (2005) ABO blood-group antigens in oral cancer. J Dent Res 84:21–28 Dabelsteen E, Grøn B, Mandel U, Mackenzie I (1998) Altered expression of epithelial cell surface glycoconjugates and intermediate filaments at the margins of mucosal wounds. J Invest Dermatol 111:592–597[CrossRef][Medline] Debets R, Hegmans JP, Croughs P, Troost RJ, Prins JB, Benner R, Prens EP (1997) The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol 158:2955–2963[Abstract] Donald ASR (1981) A-active trisaccharide isolated from A1 and A2 blood-group-specific glycoproteins. Eur J Biochem 120:243–249[Medline] Gahring LC, Buckley A, Daynes RA (1985) Presence of epidermal-derived thymocyte activating factor/interleukin 1 in normal human stratum corneum. J Clin Invest 76:1585–1591[Medline] Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69:1691–1695 Grellner W (2002) Time-dependent immunohistochemical detection of proinflammatory cytokines (IL-1β, IL-6, TNF- Halloran MM, Carley WW, Polverini PJ, Haskell CJ, Phan S, Anderson BJ, Woods JM, et al. (2000) Ley/H: an endothelial-selective, cytokine-inducible, angiogenic mediator. J Immunol 164:4868–4877 Hauser C, Saurat JH, Schmitt A, Jaunin F, Dayer JM (1986) Interleukin 1 is present in normal human epidermis. J Immunol 136:3317–3321[Abstract] Hayashi T, Ishida Y, Kimura A, Takayasu T, Eisenmenger W, Kondo T (2004) Forensic application of VEGF expression to skin wound age determination. Int J Legal Med 118:320–325[CrossRef][Medline] Ishida Y, Kondo T, Tsuneyama K, Lu P, Takayasu T, Mukaida N (2004) The pathogenic roles of tumor necrosis factor receptor p55 in acetaminophen-induced liver injury in mice. J Leukoc Biol 75:59–67 Jenkins PV, O'Donnell JS (2006) ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 46:1836–1844[CrossRef][Medline] Koch AE, Nickoloff BJ, Holgersson J, Seed B, Haines GK, Burrows JC, Leibovich SJ (1994) 4A11, a monoclonal antibody recognizing a novel antigen expressed on aberrant vascular endothelium. Upregulation in an in vivo model of contact dermatitis. Am J Pathol 144:244–259[Abstract] Kondo T, Ohshima T, Eisenmenger W (1999) Immunohistochemical and morphometrical study on the temporal expression of interleukin-1 Liu Y, Fujitani N, Koda Y, Soejima M, Kimura H (1999) Presence of H type 3/4 chains of ABO histo-blood group system in serous cells of human submandibular gland and regulation of their expression by the secretor gene (FUT2). J Histochem Cytochem 47:889–894 Macartney JC (1986) Lectin histochemistry of galactose and N-acetyl-galactosamine glycoconjugates in normal gastric mucosa and gastric cancer and the relationship with ABO and secretor status. J Pathol 150:135–144[CrossRef][Medline] Mandel U, Petersen OW, Sørensen H, Vedtofte P, Hakomori S, Clausen H, Dabelsteen E (1991) Simple mucin-type carbohydrates in oral stratified squamous and salivary gland epithelia. J Invest Dermatol 97:713–721[CrossRef][Medline] Matsui T, Shimoyama T, Matsumoto M, Fujimura Y, Takemoto Y, Sako M, Hamako J, et al. (1999) ABO blood group antigens on human plasma von Willebrand factor after ABO-mismatched bone marrow transplantation. Blood 94:2895–2900 Matsui T, Titani K, Mizuochi T (1992) Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem 267:8723–8731 Matsunaga T, Katayama I, Yokozeki H, Nishioka K (1998) Epidermal cytokine mRNA expression induced by hapten differs from that induced by primary irritant in human skin organ culture system. J Dermatol 25:421–428[Medline] Nakajima M, Ito N, Nishi K, Okamura Y, Hirota T (1988) Cytochemical localization of blood group substances in human salivary glands using lectin-gold complexes. J Histochem Cytochem 36:337–348[Abstract] Nakayama J, Ota M, Honda T, Katsuyama T (1987) Histochemical demonstration of sugar residues by lectin and immunocytochemical techniques for blood group antigens in human colon. Histochem J 19:454–464[CrossRef][Medline] O'Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA (2005) Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood 106:1988–1991 Oriol R (1995) ABO, Hh, Lewis, and secretion serology, genetics and tissue distribution. In Cartron J-P, Rouger P, eds. Blood Cell Biochemistry, vol. 6, Molecular basis of human blood group antigens. New York, Plenum Press, 37–73 Pendu JLE, Lambert F, Samuelsson B, Breimer ME, Seitz RC, Urdaniz MP, Suesa N, et al. (1986) Monoclonal antibodies specific for type 3 and type 4 chain-based blood group determinants: relationship to the A1 and A2 subgroups. Glycoconj J 3:255–271[CrossRef] Ravn V, Dabelsteen E (2000) Tissue distribution of histo-blood group antigens. APMIS 108:1–28[CrossRef][Medline] Shima M, Fujimura Y, Nishiyama T, Tsujiuchi T, Narita N, Matsui T, Titani K, et al. (1995) ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang 68:236–240[Medline] Sotozono MA, Okada Y, Tsuji T (1994) The Thomsen-Friedenreich antigen-related carbohydrate antigens in human gastric intestinal metaplasia and cancer. J Histochem Cytochem 42:1575–1584[Abstract] Takamiya M, Saigusa K, Aoki Y (2002) Immunohistochemical study of basic fibroblast growth factor and vascular endothelial growth factor expression for age determination of cutaneous wounds. Am J Forensic Med Pathol 23:264–267[CrossRef][Medline] Terui T, Hirao T, Sato Y, Uesugi T, Honda M, Iguchi M, Matsumura N, et al. (1998) An increased ratio of interleukin-1 receptor antagonist to interleukin-1 Zezos P, Papaioannou G, Nikolaidis N, Vasiliadis T, Giouleme O, Evgenidis N (2005) Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation. World J Gastroenterol 11:7639–7645[Medline] Zhu K, Amin MA, Kim MJ, Katschke KJ Jr, Park CC, Koch AE (2003) A novel function for a glucose analog of blood group H antigen as a mediator of leukocyte-endothelial adhesion via intracellular adhesion molecule 1. J Biol Chem 278:21869–21877
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||